BioCardia Inc.
| NASDAQ: BCDA | Healthcare / Biotechnology / USA |
| 4.20 | +0.1900 | +4.74% | Vol 120.40K | 1Y Perf 39.36% |
| Apr 13th, 2021 16:00 DELAYED |
| BID | 4.17 | ASK | 4.22 | ||
| Open | 4.07 | Previous Close | 4.01 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 10.63 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 153.10 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★+ 49.71 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★+ 49.32 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 68.62M | Earnings Rating | — | |
| Price Range Ratio 52W % | 34.23 | Earnings Date | 21st May 2021 |
Today's Price Range 4.024.25 | 52W Range 1.918.60 | 5 Year PE Ratio Range -2.70915.40 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | -8.89% | ||
| 1 Month | 5.00% | ||
| 3 Months | 12.00% | ||
| 6 Months | 77.97% | ||
| 1 Year | 39.36% | ||
| 3 Years | -68.25% | ||
| 5 Years | -49.49% | ||
| 10 Years | -35.19% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -118.86 | |||
ROE last 12 Months | -137.93 | |||
ROA (5Y Avg) | -88.57 | |||
ROA last 12 Months | -94.41 | |||
ROC (5Y Avg) | -166.22 | |||
ROC last 12 Months | -263.20 | |||
Return on invested Capital Q | -23.76 | |||
Return on invested Capital Y | -128.93 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.80 | ||||
| 3.88 | ||||
| 629.15 | ||||
| 26.20 | ||||
| -7.90 | ||||
| -1.22 | ||||
| 3.88 | ||||
| 1.14 | ||||
| 53.58M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.20 | ||||
| 5.30 | ||||
| 0.09 | ||||
| 0.03 | ||||
| -5 000.30 | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 97.20 | ||||
| -4 940.80 | ||||
| -4 913.70 | ||||
| -3 803.30 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 107.00K | ||||
| 0.01 | ||||
| -31.76 | ||||
| -14.74 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.31 | -0.16 | 48.39 |
| Q03 2020 | -0.28 | -0.30 | -7.14 |
| Q02 2020 | -0.25 | -0.46 | -84.00 |
| Q01 2020 | -0.32 | -0.67 | -109.38 |
| Q04 2019 | - | -0.51 | - |
| Q03 2019 | -0.43 | -0.55 | -27.91 |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 21st May 2021 |
| Estimated EPS Next Report | -0.16 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 120.40K |
| Shares Outstanding | 16.34M |
| Trades Count | 544 |
| Dollar Volume | 758.19K |
| Avg. Volume | 299.13K |
| Avg. Weekly Volume | 214.79K |
| Avg. Monthly Volume | 178.38K |
| Avg. Quarterly Volume | 283.44K |
BioCardia Inc. (NASDAQ: BCDA) stock closed at 4.2 per share at the end of the most recent trading day (a 4.74% change compared to the prior day closing price) with a volume of 120.40K shares and market capitalization of 68.62M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 24 people. BioCardia Inc. CEO is Peter Altman.
The one-year performance of BioCardia Inc. stock is 39.36%, while year-to-date (YTD) performance is 21.39%. BCDA stock has a five-year performance of -49.49%. Its 52-week range is between 1.91 and 8.6, which gives BCDA stock a 52-week price range ratio of 34.23%
BioCardia Inc. currently has a PE ratio of -2.80, a price-to-book (PB) ratio of 3.88, a price-to-sale (PS) ratio of 629.15, a price to cashflow ratio of 26.20, a PEG ratio of 2.32, a ROA of -94.41%, a ROC of -263.20% and a ROE of -137.93%. The company’s profit margin is -%, its EBITDA margin is -4 913.70%, and its revenue ttm is $107.00 Thousand , which makes it $0.01 revenue per share.
Of the last four earnings reports from BioCardia Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.16 for the next earnings report. BioCardia Inc.’s next earnings report date is 21st May 2021.
The consensus rating of Wall Street analysts for BioCardia Inc. is Strong Buy (1), with a target price of $10.63, which is +153.10% compared to the current price. The earnings rating for BioCardia Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioCardia Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioCardia Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.80, ATR14 : 0.39, CCI20 : -59.38, Chaikin Money Flow : -0.02, MACD : -0.14, Money Flow Index : 65.21, ROC : -3.45, RSI : 40.15, STOCH (14,3) : 38.60, STOCH RSI : 0.94, UO : 41.58, Williams %R : -61.40), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioCardia Inc. in the last 12-months were:
BioCardia Inc.
BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack.
CEO: Peter Altman
Telephone: +1 650 226-0120
Address: 125 Shoreway Road, San Carlos 94070, CA, US
Number of employees: 24
